Nanxin Pharmaceutical: Abnormal stock trading fluctuations planned to purchase pharmaceutical technology assets group matters.

Nanxin Pharmaceutical issues a notice regarding abnormal fluctuations in stock trading. The closing price of the company's stock has deviated by a cumulative 30% for three consecutive trading days, which falls under the category of abnormal fluctuations in stock trading according to relevant regulations. The company is currently planning to acquire certain domestic pharmaceutical technology assets, but it is not yet certain if this will constitute a major asset restructuring. This matter is still in the planning stage, no intent agreement regarding the acquisition has been signed yet, and there is significant uncertainty as to whether it can be successfully implemented. The company will fulfill its disclosure obligations in a timely manner based on the progress of this matter.